Mega Genomics Ltd. (6667)

Overview

Mega Genomics Limited is a pioneering company domiciled in Beijing, China, specializing in genetic testing. Founded in 2016, it has rapidly positioned itself as a significant player in the genetic testing industry within China. The company offers a wide array of services aimed at providing valuable health-related genetic insights to its customers. These services range from consumer genetic testing to comprehensive cancer screenings. Mega Genomics serves a diverse clientele, including health checkup centers, hospitals, and individual consumers, leveraging advanced technologies to assess genetic predispositions to various diseases and conditions.

Products and Services

General Testing Services:

• Brain Health Assessment Package: Evaluates the genetic risk for numerous brain-related diseases, highlighting Alzheimer's disease. This service aids in understanding individual predisposition to such conditions.
• Alimentation Capability Assessment Package: Identifies genetic risks related to hyperhomocysteinemia, enabling a proactive approach to diet and health management.
• Parkinson’s Disease Risk Assessment: Provides an analysis of genetic predisposition to Parkinson’s disease, facilitating early awareness and potential intervention strategies.
• Full-Scale Cancer Risk Assessment Packages: Comprehensive genetic testing for assessing the risk of various cancers, aiming to support early detection and prevention efforts.
• Cardiovascular and Cerebrovascular Disease Risk Assessment Packages: Evaluates the genetic risk for heart and cerebrovascular diseases, critical for preventive health strategies.

Advanced Testing Services:

• Hereditary Breast Cancer/Ovarian Cancer Genetic Testing: Offers specialized testing for genes associated with increased risk of breast and ovarian cancer, crucial for early intervention and management.
• Septin9 Colorectal Cancer Screening Test: Utilizes the Septin9 biomarker for non-invasive screening of colorectal cancer, enhancing early detection possibilities.
• RNF180/Septin9 Gastric Cancer Screening Test: Focuses on the detection of genetic markers associated with an elevated risk of gastric cancer, offering a non-invasive screening option.

Executive Testing Services:

• Personal Whole Genome Test: Provides a comprehensive analysis of an individual’s entire genome, offering extensive insights into genetic health risks and traits.
• Whole-Exome Sequencing Package for Adults: Examines the exome, a critical part of the genome that codes for proteins, to detect genetic variants that might influence health and disease predisposition.